ARS Pharmaceuticals, Inc. Chief Legal Officer John L. Slebir filed a statement of changes in beneficial ownership on November 4, 2026, disclosing the acquisition of stock options on November 2, 2026.

Key Highlights

  • Reporting person: John L. Slebir, Chief Legal Officer of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)
  • Transaction date: November 2, 2026, with the filing submitted November 4, 2026
  • Security acquired: A stock option (right to buy) covering 1,199,482 shares of Common Stock, acquired with transaction code "A"
  • Exercise price: $3.05 per share, with a price of $0 noted for the derivative security itself
  • Expiration date: November 1, 2036
  • Vesting schedule: 25% of shares vest on October 26, 2027, with the remainder vesting monthly over the following three years
  • Beneficial ownership following transaction: 1,199,482 derivative securities held directly

Stock Option Grant to ARS Pharmaceuticals Chief Legal Officer

According to the filing, John L. Slebir, who serves as Chief Legal Officer of ARS Pharmaceuticals, Inc., was granted a stock option covering 1,199,482 shares of the company's Common Stock on November 2, 2026. The option carries an exercise price of $3.05 per share and is set to expire on November 1, 2036. The filing lists the price of the derivative security itself as $0. ARS Pharmaceuticals, Inc. is a pharmaceutical company whose shares trade on NASDAQ under the symbol SPRY.

The filing discloses a specific vesting schedule tied to the grant. As stated in the explanation of responses, "25% of the shares subject to the option vest on October 26, 2027, and the remaining shares will vest monthly thereafter over three years." Following this transaction, Slebir is reported to beneficially own 1,199,482 derivative securities in direct ownership form, with no holdings reported in Table I covering non-derivative securities.

The form was signed by Kathleen Scott, identified as Attorney-in-Fact, and dated November 4, 2026. The filing indicates that it was submitted by one reporting person and that no amendment date applies, meaning this is an original filing rather than a revision of a previously submitted disclosure.

What Was Disclosed

ARS Pharmaceuticals, Inc. Chief Legal Officer John L. Slebir reported the acquisition of a stock option covering 1,199,482 shares of Common Stock at an exercise price of $3.05, expiring November 1, 2036, with a four-year vesting schedule beginning October 26, 2027.